In the case presented, the myeloblasts were positive for CD34 (Image 3B), megakaryocytes were identified by factor VIII related antigen and CD71
highlighted erythroid precursors (not shown).
These still-developing cells, which have a protein on their surface called CD71
, also show up in abundance in the umbilical cord blood of human babies, the team showed.
Instead, however, markers of lymphocyte activation (CD30, CD38, CD71
, epithelial membrane antigen, human leukocyte antigen-DR) and plasma cell differentiation (CD138) are often present.
For immunophenotyping, cord blood samples were labelled with CD45, CD34, HLA-DR, CD38, CD71
, CD90, and CD135 after blood count.
The gull isolate AV7 was indistinguishable from human isolates CD71
, SA115, and CM1 by MLST and has the same mating type (a/[alpha]).
Pan B-cell markers (CD19, CD20) are negative, but cells are positive for CD45 and activation-associated antigens CD30, CD38, CD71
, and EMA.
Myeloid CD markers CD Marker Result CD11b 3+ CD13 (LeuM7 pos CD14 (LeuM3) neg CD15 (LeuM1) neg CD33 (LeuM9) pos CD34 (My10) 2+ CD45 (HLE) pos CD61 (gp3a) 1+ CD64 neg CD71
pos CD117 pos HLA-DR neg Table 3.
Table 2 Selected flow cytometry panels and their objectives Antibody panel Objective CD5, CD19 CD10 Detects chronic lymphocytic leukemia CD20 CD11c, CD22 Detects B-cells or hairy cells CD33, CD13, HLADr Resolves myeloid leukemia cells CD7, CD1, CD2 Defines mature and immature T-cells subsets CD38, CD56, CD45 Resolves plasma and myeloma cells CD5 CD14 CD19 Defines T and B cells and monocytes in cerebral spinal fluid CD16 CD13, HLADr Defines acute promyelomonocytic leukemia CD71
, CD3, CD4 Activation of T-helper/inducer cell subset CD20, CD79, CD22 Evaluation of CD79 to resolve certain B-cell malignancies CD33, UIC2, CD34 Evaluate drug resistance or progenitor cells Source: Roswell Park Cancer Institute
8,9) Additional positive markers include CD9, CD11c, CD29, CD33, CD43, CD44, CD45, CD49d, CD49e, CD51, CD54, CD71
, and the high-affinity immunoglobulin E receptor.
Calcineurin also directly activates the lymphocytes by upregulating the expression of T-cell surface receptors, including the IL-2 receptor [alpha] chain CD25 and the transferin receptor CD71
3]) Common Nodal and extranodal Effusions presentation Tumour cell size Small--large Large CD45 (LCA) Positive (may be lost) Positive CD20 Positive (may be lost) Rare positive BCL6 Rare positive Rare positive Other positive CD10 CD30 markers CD31 CD71
CD56 CD31 EMA CD138 Positive Positive CD38 Positive Positive MUM1 Positive Positive Proliferation High (75-95%) High (>80%) index (Ki-67) Paraprotein Absent Absent EBV Positive (80%) Positive (90%) HHV8 Controversial positive Positive Genetic features MYC activation Rare chromosome p53 overexpression abnormalities Lymphoma type Solid PEL Polyclonal lymphoma CD4 cell count Low (<200) Low (<20O) (cells/[mm.
Moderate to bright expression of CD71
(transferrin receptor) and glycophorin A (CD235a) provides evidence of erythroid differentiation, but it should be noted that dim expression of the former is seen on many activated cell types, including neoplastic myeloblasts.